Fact based stock research
Zymeworks (NYSE:ZYME)

CA98985W1023

Zymeworks stock research in summary

zymeworks.com


Zymeworks shares are more expensive than other comparable stocks. They are riskily financed, show below average growth, and are poor value. We recommend evaluating whether the future of the company Zymeworks is really as positive as the high price of the shares suggests. If you come to the conclusion that the future for this company is only average, that could be a reason to sell this share.


Latest Obermatt Ranks


Country Canada
Industry Biotechnology
Index
Size class X-Small

November 18, 2021. Stock data may be delayed. Login to get the most recent research.

Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Zymeworks from November 18, 2021.

We invest in our stock tips ourselves and openly publish the returns of our portfolio. That's how much we believe in our stock research. Subscribe to the top 10 stocks for 100 markets conveniently by e-mail.